Skip to main content
. 2019 Mar 6;9:3710. doi: 10.1038/s41598-019-40124-5

Figure 1.

Figure 1

Flow cytometry for integrin β7 and CD62L in IBS patients and HV. (A) Flow cytometry revealed a significant increase in the % of CD4+ T-cells expressing the gut homing marker, integrin β7, in patients with IBS (38.3% [34.8–43.1], n = 12) when compared to HV (30.2% [22.5–35.6], n = 12; p = 0.023 vs. IBS). A significant increase in the % of CD4+ T-cells expressing the lymph node homing marker, CD62L was also seen in IBS (B) (IBS: 85.2% [83.3–88.9], n = 12; HV: 80.1% [73.5–84.4], n = 12; p = 0.026), as well as in the % of CD4+ T-cells co-expressing CD62L and integrin β7 (C) (IBS: 35.6% [30.2–42.2], n = 12; HV: 27.3% [17.4–32.5], n = 12; p = 0.040, when compared to HV).